216 (2020): 165-172.e4
service as a consultant for AstraZeneca, Bayer Healthcare Pharmaceuticals, Biomea Fusion, Boehringer Ingelheim, Carmot, Eli Lilly, Intarcia, Intercept Pharmaceuticals, Janssen Global Services, Johnson & Johnson Medical Devices & Diagnostics GroupLatin America, MannKind Corporation, Merck, Novo Nordisk, Pfizer, Sanofi US Services, Shionogi, Structure Therapeutics, Target Pharma, Valeritas and Zealand Pharma A/S
DPP-4 inhibitors in clinical use today exhibit little or no binding to either DPP-8 or DPP-9
The intestinal cell metaplasia in cholangiofibrosis includes goblet and Paneth cells and columnar cells similar to chief cells identified in H&E-stained paraffin sections and enterochromaffin cells identified by special staining
The aliquotation process is performed under a quality and manufacturing agreement between Evidentic and the contract manufacturer